M04.2
Cryopyrin-associated periodic syndromes
Clinical Classification Guidelines
Inclusion Terms
- Chronic infantile neurological, cutaneous and articular syndrome [CINCA]
- Familial cold autoinflammatory syndrome
- Familial cold urticaria
- Muckle-Wells syndrome
- Neonatal onset multisystemic inflammatory disorder [NOMID]
Medical Intelligence & Overview
Cryopyrin-associated periodic syndromes (CAPS) are a group of rare, inherited autoinflammatory conditions characterized by episodes of systemic inflammation. These conditions often affect multiple systems in the body, including the skin, joints, and nervous system. CAPS are caused by genetic mutations that lead to abnormal activation of the immune system’s inflammatory pathways. The syndrome spectrum includes several distinct, yet related disorders such as Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal-Onset Multisystem Inflammatory Disorder (NOMID).
Causes & Symptoms
Clinical Causes: Genetic mutations in the NLRP3 gene (also known as CIAS1) Inheritance pattern is typically autosomal dominant Spontaneous mutations can also occur, leading to disease in individuals with no family history
Key Symptoms: Recurrent episodes of fever Skin rashes, especially urticaria-like (hives) Joint pain and swelling Headaches and neurological symptoms such as chronic meningitis or brain inflammation Eye inflammation, including conjunctivitis or uveitis Hearing loss Inflammation of various internal organs in severe cases Neonatal symptoms may include irritability, persistent fever, and multisystem involvement
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation and laboratory tests. Key steps include: - Thorough medical history and physical examination to identify recurrent inflammatory episodes - Blood tests measuring markers of inflammation such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) - Genetic testing to identify mutations in the NLRP3 gene - Imaging studies if neurological or joint involvement is suspected - Rule out other causes of systemic inflammation The diagnosis is often confirmed through genetic testing that detects NLRP3 gene mutations, especially in patients with characteristic clinical features.
Treatment Protocols: While there is no cure for CAPS, treatments focus on managing and reducing the frequency and severity of flare-ups. Common approaches include: - Targeted therapies such as interleukin-1 (IL-1) inhibitors (e.g., anakinra, canakinumab, rilonacept) which block inflammation pathways - Non-steroidal anti-inflammatory drugs (NSAIDs) for mild symptoms - Corticosteroids in some cases to control inflammation - Regular monitoring and supportive care to manage complications such as hearing loss or neurological issues - Physical therapy for joint symptoms Early diagnosis and treatment with IL-1 inhibitors can significantly improve quality of life and prevent long-term complications.
Clinical Advice & FAQs
Billing Guidance
Is M04.2 a billable ICD-10 code?
Yes, M04.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M04.2?
Clinical documentation must specify the nature of Cryopyrin-associated periodic syndromes and any associated comorbidities for accurate reporting.
Cite this Clinical Reference